Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Pech T et al. | Combination therapy of tacrolimus and infliximab reduces inflammatory response and dysmotility in experimental small bowel transplantation in rats. | 2012 | Transplantation | pmid:22167049 |
Gayowski T et al. | Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. | 1998 | Transplantation | pmid:9500623 |
Hougardy JM et al. | The once-daily formulation of tacrolimus: a step forward in kidney transplantation? | 2012 | Transplantation | pmid:22234346 |
D'Antiga L et al. | Late cellular rejection in paediatric liver transplantation: aetiology and outcome. | 2002 | Transplantation | pmid:11792983 |
Deuse T et al. | The interaction between FK778 and tacrolimus in the prevention of rat cardiac allograft rejection is dose dependent. | 2004 | Transplantation | pmid:15084926 |
Ferraris JR et al. | Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection: changes in the immune responses. | 2004 | Transplantation | pmid:15084930 |
Xu X et al. | FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. | 2002 | Transplantation | pmid:12085010 |
Jin S et al. | Effect of tacrolimus on the expression of macrophage scavenger and nuclear hormone receptors in THP-1-derived human macrophages. | 2004 | Transplantation | pmid:15114099 |
Straatman LP and Coles JG | Pediatric utilization of rapamycin for severe cardiac allograft rejection. | 2000 | Transplantation | pmid:10949201 |
Burke GW et al. | Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement. | 1999 | Transplantation | pmid:10573073 |
Takatsuki M et al. | Weaning of immunosuppression in living donor liver transplant recipients. | 2001 | Transplantation | pmid:11502975 |
Suzuki S et al. | Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. | 1993 | Transplantation | pmid:7685932 |
Augustine JJ et al. | Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. | 2006 | Transplantation | pmid:16612276 |
Brunet M et al. | Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. | 2006 | Transplantation | pmid:16495801 |
Hougardy JM et al. | Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. | 2011 | Transplantation | pmid:21192316 |
Vanrenterghem Y et al. | The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. | 2004 | Transplantation | pmid:15257032 |
van Hooff JP et al. | Tacrolimus and posttransplant diabetes mellitus in renal transplantation. | 2005 | Transplantation | pmid:15940032 |
Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
Markus PM et al. | Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. | 1991 | Transplantation | pmid:1718063 |
Wiesner RH | A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. | 1998 | Transplantation | pmid:9734494 |